Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis-Associated Pain

Trial Profile

Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis-Associated Pain

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elagolix (Primary)
  • Indications Endometriosis; Pelvic pain
  • Focus Registrational; Therapeutic Use
  • Acronyms Elaris EM-IV; EM-IV
  • Sponsors AbbVie
  • Most Recent Events

    • 06 Jun 2018 Results from two extension studies assessing long terms outcomes of Elagolix in women with Endometriosis (NCT01760954 (n=287) and NCT02143713 (n=282)), published in the Obstetrics and Gynecology Journal.
    • 30 Apr 2018 Results presented at the 66th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists
    • 30 Apr 2018 Results of pooled data from two phase 3 trials (Elaris EM-III and IV) assessing long-term safety and efficacy of elagolix treatment in women with endometriosis-associated pain, were presented at the 66th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top